Protara Therapeutics (NASDAQ:TARA) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Protara Therapeutics (NASDAQ:TARA) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning.

Other analysts also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Friday, July 17th. Oppenheimer increased their price target on shares of Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. UBS Group reiterated a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Finally, JPMorgan Chase & Co. decreased their price objective on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $26.25.

Protara Therapeutics Stock Performance

Shares of TARA opened at $3.97 on Friday. The company’s fifty day moving average is $4.02 and its 200 day moving average is $5.02. Protara Therapeutics has a fifty-two week low of $2.97 and a fifty-two week high of $7.82. The stock has a market capitalization of $234.63 million, a PE ratio of -2.94 and a beta of 1.50.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). As a group, research analysts forecast that Protara Therapeutics will post -1.48 earnings per share for the current year.

Institutional Trading of Protara Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its holdings in Protara Therapeutics by 133.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock valued at $2,767,000 after buying an additional 304,110 shares in the last quarter. AIGH Capital Management LLC purchased a new stake in Protara Therapeutics in the 1st quarter valued at about $8,454,000. UBS Group AG grew its stake in Protara Therapeutics by 44.2% in the 4th quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock worth $6,479,000 after acquiring an additional 372,463 shares in the last quarter. Walleye Capital LLC grew its stake in Protara Therapeutics by 204.0% in the 1st quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock worth $2,310,000 after acquiring an additional 297,525 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its position in shares of Protara Therapeutics by 81.0% during the fourth quarter. Baker BROS. Advisors LP now owns 971,614 shares of the company’s stock worth $5,179,000 after acquiring an additional 434,782 shares during the period. 38.13% of the stock is currently owned by institutional investors.

Key Headlines Impacting Protara Therapeutics

Here are the key news stories impacting Protara Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating. Although the firm lowered several EPS estimates, it still expects Protara to become profitable over the longer term, forecasting positive EPS of $0.56 in fiscal 2029 and $1.09 in fiscal 2030.
• Neutral Sentiment: Wall Street Zen downgraded its stock rating. The rating cut may weigh on investor sentiment, although the report provides no details in the supplied headline regarding the new rating or the rationale. Protara Therapeutics Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: HC Wainwright reduced its near- and long-term earnings projections. The firm lowered its Q3 and Q4 2026 EPS forecasts to $(0.36) from $(0.31), FY2026 EPS to $(1.38) from $(1.24), and FY2027 EPS to $(1.50) from $(1.37). It also reduced FY2028 EPS to $(0.43) from $(0.34), FY2029 EPS to $0.56 from $0.60, and FY2030 EPS to $1.09 from $1.10. The revisions imply deeper expected losses in the next several years and slightly less profitability thereafter.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.